News comes on heels of recent expanded U.S. payer coverage, reaching 96% of commercially and Medicare insured lives, expanding greater access to care Medtronic, a global leader in healthcare technology, announced new prospective findings from the VenaSeal™ Spectrum Program, further strengthening the evidence supporting the VenaSeal™ closure system across chronic venous disease. The findings were presented at the 2026 Venous Endovascular INterventional Strategies 2026 [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.